Phase III Abarelix data

Praecis (PRCS) and partner Amgen (AMGN) presented results of two Phase III trials of Abarelix Depot-M, a luteinizing hormone releasing hormone ( LHRH)/gonadotropin releasing hormone (GnRH) antagonist to treat prostate cancer. In a 271-patient U.S. Phase III trial, 100 percent of patients receiving 100 mg Abarelix intramuscularly avoided a surge of testosterone compared to 18 percent of patients receiving leuprolide (p<0.001), and 72 percent of Abarelix patients achieved medical castration by day 8 compared to 0 leuprolide patients (p<0.001). Both Abarelix and leuprolide produced sustained medical castration through 12 weeks in >90 percent of patients, and both were well tolerated. ...